GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InnoCan Pharma Corp (XCNQ:INNO) » Definitions » LT-Debt-to-Total-Asset

InnoCan Pharma (XCNQ:INNO) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is InnoCan Pharma LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. InnoCan Pharma's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

InnoCan Pharma's long-term debt to total assets ratio declined from Dec. 2022 (0.00) to Dec. 2023 (0.00). It may suggest that InnoCan Pharma is progressively becoming less dependent on debt to grow their business.


InnoCan Pharma LT-Debt-to-Total-Asset Historical Data

The historical data trend for InnoCan Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCan Pharma LT-Debt-to-Total-Asset Chart

InnoCan Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.02 - - - -

InnoCan Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

InnoCan Pharma LT-Debt-to-Total-Asset Calculation

InnoCan Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=0.015/9.311
=0.00

InnoCan Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=0.015/9.311
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InnoCan Pharma  (XCNQ:INNO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


InnoCan Pharma LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of InnoCan Pharma's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


InnoCan Pharma (XCNQ:INNO) Business Description

Traded in Other Exchanges
Address
1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals. Geographically, it derives a majority of its revenue from the United States.

InnoCan Pharma (XCNQ:INNO) Headlines

From GuruFocus

President of Innocap, Inc. is in Singapore

By Marketwired Marketwired 05-03-2018

President of Innocap, Inc. is in Singapore

By GlobeNewswire GlobeNewswire 05-03-2018

Innocap, Inc.'s Current Activities

By Marketwired Marketwired 05-24-2018

Innocap, Inc. Year End Message To Shareholders

By PRNewswire PRNewswire 12-14-2020